Net Cash Provided by (Used in) Financing Activities in USD of Sarepta Therapeutics, Inc. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Sarepta Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2010 to Q1 2025.
  • Sarepta Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $12.5M, a 43.7% decline year-over-year.
  • Sarepta Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $125M, a 0.16% decline from 2023.
  • Sarepta Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $125M, a 46.2% decline from 2022.
  • Sarepta Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $233M, a 58.6% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Sarepta Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $12.5M -$9.67M -43.7% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q1 2024 $22.1M -$79.7M -78.3% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q1 2023 $102M +$96.8M +1940% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q1 2022 $4.99M +$2.1M +72.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q1 2021 $2.89M -$316M -99.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q1 2020 $319M -$58.5M -15.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q1 2019 $378M +$370M +4954% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q1 2018 $7.47M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q1 2013 $2.97M +$2.99M Jan 1, 2013 Mar 31, 2013 10-Q 2013-05-09
Q1 2012 -$20K* -$116K Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-09
Q1 2011 $96K* Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-10

Sarepta Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $125M -$198K -0.16% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-28
2023 $125M -$108M -46.2% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-28
2022 $233M -$329M -58.6% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-28
2021 $562M -$121M -17.7% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $682M +$39.8M +6.19% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $643M +$112M +21.2% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $530M -$358M -40.3% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-01
2017 $888M +$510M +135% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 $378M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2013 $146M -$32.9M -18.4% Jan 1, 2013 Dec 31, 2013 10-K 2014-03-03
2012 $179M +$146M +453% Jan 1, 2012 Dec 31, 2012 10-K 2014-03-03
2011 $32.3M +$29.8M +1200% Jan 1, 2011 Dec 31, 2011 10-K 2014-03-03
2010 $2.48M Jan 1, 2010 Dec 31, 2010 10-K 2013-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.